Live attenuated zika vaccine development in brazil
Ended Awarded Last action
- Contract number
- HHSN26100056
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,038,844
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $12,038,844.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $12,038,844 |
About this award
This is a federal contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Leidos Biomedical Research Inc. for the development of a live attenuated Zika vaccine in Brazil. The $12,038,844.00 contract is a cost-plus-fixed-fee delivery order that runs from September 2017 to September 2022. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and has performed extensive research and development work for the NIH, including supporting biomedical research programs and providing facilities operations and maintenance, manufacturing, and clinical trials management services. This contract is not associated with a set-aside program.
Quick answers
Who was awarded contract HHSN26100056?
HHSN26100056 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2017.
How much is contract HHSN26100056 worth?
The government has obligated $12,038,844 on HHSN26100056.
Which agency awarded contract HHSN26100056?
National Cancer Institute (National Institutes of Health) awarded HHSN26100056, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100056 an order under another contract?
Yes. HHSN26100056 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100056 competed?
The extent of competition for HHSN26100056 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award